GLP-1 therapies have made clear that pharmacological treatment for obesity works. Now, the field is moving into more complex territory. Regulators have already approved indications for cardiovascular risk reduction, MASH, and sleep apnea, among others. To fully address these patient populations, pharma companies face three rigorous tests:
1. Prove these drugs deliver more than weight loss
2. Build the care infrastructure to support patients over years, not months
3. Earn trust in a fast-moving market
Newer drug classes, including triple agonists, amylin-based combinations, and oral formulations, will continue to widen the field. Each new indication and mechanism adds another population, another evidence requirement, and another layer of complexity for the systems meant to deliver these therapies.
Moving forward with GLP-1 therapies will first require a few steps back. That’s because the systems meant to absorb them have not caught up with pharma’s scientific advances. Payers are still unresolved on affordability, appropriate use, and long-term coverage. Primary care is being asked to manage complex, chronic metabolic treatment without the infrastructure or clinical backup to do it well. And patients are arriving with expectations shaped by social media and hype, not by clinical reality.
The playbook from the first wave of GLP-1s simply won't be enough for what comes next. Success will belong to pharma companies that rebuild their evidence, their operating model, and their engagement strategy around all three tests.
From pounds lost to long-term disease control
The primary case for GLP-1 therapies for obesity treatment was built on one number: pounds lost. That number opened the door, but it’s not enough to keep it open.
Payers, providers, employers, and patients are starting to ask harder questions:
- How does treatment affect cardiovascular risk, physical function, and long-term disease progression?
- How does it reduce downstream costs?
- Who benefits the most, and for how long?
These are evidence strategy questions that hinge on whether pharma companies can connect how a drug performs in clinical trials to real-world outcomes decision-makers care about.
Osteoarthritis illustrates the case. Chronic joint pain from excess weight often becomes a downward spiral: painkillers that themselves promote weight gain, rising surgical risk, and a toll on mental health. Musculoskeletal conditions are already a leading cause of long-term disability and lost work.
If GLP-1s can treat the root cause instead of managing its downstream effects, the value case extends beyond drug cost into employer healthcare and public health spending.
To prove value, pharma companies must build evidence around who benefits from treatment and how.
Long-term care, not a one-time launch
Metabolic therapies are shifting treatment into primary care, telehealth, and pharmacy-linked models. However, most pharma companies built their pipelines and capabilities for obesity treatment led by specialists.
The mismatch shows up when treatment stops. Data from the STEP 1 trial extension found that patients who stopped semaglutide regained most of their weight within a year and lost the cardiometabolic benefits they had achieved.
Other chronic conditions don't work this way. Discontinuing blood pressure medication when a patient's numbers normalize, only to watch them climb again, would be considered a clear lapse in care. Obesity treatment needs to be managed with the same logic.
To build the infrastructure to support long-term weight control, pharma field teams must support primary care physicians from product education through long-term management decisions. They also need systems built around patient retention, as well as Medical Affairs functions intended to help healthcare systems design long-term care pathways.
Trust is a commercial asset
Patients are forming opinions about GLP-1s based on social media, AI tools, peer networks and digital clinics. Many arrive at appointments equipped with their own research and expectations, not all of it accurate.
Pharma companies must pay attention to, and engage in, these conversations. Patients who start treatment with inflated expectations, or no clear picture of what happens if they stop, are more likely to quit early. And discontinuation undermines both clinical and commercial outcomes.
Employers and payers are also listening to the GLP-1 conversation and weighing near-term cost against long-term benefit. In a saturated media environment, brand trust is a commercial strength companies will need as the market matures.
What this means for pharma
The challenges facing GLP-1 therapies differ across evidence, operations and trust, but the pattern is consistent: the science has outrun the systems built to support it.
On evidence, headline weight loss can no longer carry differentiation on its own. Value strategies need to be rebuilt around specific patient populations and outcomes.
On operations, a strong asset is necessary but not sufficient. Sustained results depend on care models built for chronic management, not just launch.
On trust, expectations are forming faster than pharma can control them. Durable engagement will come from real insight into how those expectations form, not just a communications plan.
The question now is which pharma company can move beyond strategy and deliver the evidence, operations and trust the market demands.
For a deeper dive into GLP-1s’ long-term impact on healthcare, explore our white paper: "From GLP-1 Breakthrough to Healthcare System Readiness.” Download Now.
